April 25, 2016

Goldman Sach's 5 Large-Cap Pharma Stock Favorites Ahead of Earnings


Large-cap pharmaceutical stocks have underperformed the S&P 500 this year, pressured by the political climate and earnings estimate revisions, according to Goldman Sachs.

"While a challenging macro environment including pricing scrutiny is likely to persist, we expect in line [first-quarter] results with FX (foreign exchange) reversal tailwinds driving upside to guidance," Goldman analysts led by Jami Rubin wrote in a note on Friday, noting that investors in pharmaceuticals have been too distracted by currency issues, which seem to finally be subsiding.

Here's a look at Goldman's top picks for the pharma sector as the group gets ready to report quarterly earnings results...

Source: TheStreet